AI development with Janssen – News – Merck Global | Merck global

02 Jul 2020 | Darmstadt, Germany
  • Combined efforts aim to develop an artificial intelligence (AI) technology that detects both schistosomiasis and soil-transmitted helminthiasis
  • AI technology has the potential to improve diagnostic efficiency, data accuracy and decision making for mass drug administration programs
  • Merck has been fighting against the neglected tropical disease schistosomiasis since 2007 

Merck, a leading science and technology company, today announced that it has entered into an agreement with Janssen Pharmaceutica, N.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson, to develop an Artificial Intelligence (AI) based diagnostic tool to improve the detection of the Neglected Tropical Diseases (NTDs) schistosomiasis and soil-transmitted helminthiasis (STH).

“The world is currently facing a major health crisis while vulnerable patients suffering from NTDs continue to require treatment and care,” said Béatrice Greco, Head of Research & Development at Merck Global Health Institute. “We are extremely proud of this unique partnership with Janssen. Together, we are joining forces to improve the accuracy of diagnostic methods used for several NTDs and to reduce the burden of reporting and surveillance for countries.”

Control and gradual elimination of these diseases are crucial and require the development of advanced innovative technologies to diagnose patients, who are often co-infected with multiple pathogens. Data quality is an essential component of making informed treatment decisions and coordinating mass drug administration campaigns that target NTDs.

More:  Merck Receives Priority Review from FDA for Second Application for KEYTRUDA® (pembrolizumab) Based on Biomarker, Regardless of Tumor Type

The prototype which is currently being tested consists of an automated microscope with AI and data visualization tool. The AI counts parasite eggs that would develop into parasitic worms of either schistosomiasis or STH. This automated counting process is aimed at being both faster and more reliable than the current survey method, in which a lab technician counts the eggs in each sample manually. Digital data storage and data visualization will improve the clinical decision making for drug administration by the countries. The prototype testing will continue throughout 2020 and move into the clinical utility testing phase in 2021 through 2023.

Schistosomiasis is a chronic condition and one of the most common and most devastating parasitic diseases in tropical countries.  Merck has been fighting against this NTD with its partner, the World Health Organization (WHO), since 2007 in the scope of its Merck Schistosomiasis Elimination Program and donates up to 250 million of praziquantel tablets for treatment per year. Merck and WHO committed themselves to continue their work in fighting the disease until its elimination. Merck has been implementing a comprehensive approach combining treatment, research and development, health education and WASH (water, sanitation and hygiene) to control transmission and eliminate the disease.

More:  Merck Broadens Patient Support and Assistance Programs as Part of Overall COVID-19 Relief Efforts

Merck uses AI in many different areas of its three businesses. In its Healthcare business for example, Merck uses AI in drug discovery as a way to accelerate the process and to reduce its costs. Other AI use cases have been made in areas as diverse as material sciences, digital pathology or information extraction from patents. Merck also cooperates with other companies in the area of AI such as Iktos, Cyclica, China’s Ping An Good Doctor and Aera Technology. Additionally, an interdisciplinary team of mathematicians, computer scientists, and neuroscientists aims to rethink the foundations of artificial and biological intelligence as an inhouse research team.

More from: | Category: Pharmaceutical Company News